We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04287686
Recruitment Status : Withdrawn (Without CDE Approval)
First Posted : February 27, 2020
Last Update Posted : March 17, 2020
Sponsor:
Information provided by (Responsible Party):
Yimin LI, The First Affiliated Hospital of Guangzhou Medical University

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Withdrawn
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2020
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):